Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine Among Older and Frail Patients..
Dec 19, 2023
The authors of this multicenter, noninferiority, phase III trial evaluated the safety and efficacy of oxaliplatin and capecitabine in elderly frail patients with advanced gastroesophageal cancer. Oxaliplatin and capecitabine were dosed at level A, level B (80% of level A), or level C (60% of level A) in the chemotherapy-intensive arm, or patients were treated with best supportive care. The progression-free survivals associated with both levels B and C were noninferior to level A. Dose level C was associated with the best overall treatment utility. In the group in which chemotherapy was compared with best supportive care, the overall survival was numerically longer for chemotherapy, but this was not statistically significant.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…